Coverage for Mild Alzheimer's Disease Treatments
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
- Sex
- Any
- Study type
- Observational
- Participants needed
- 8,680 (estimated)
- Sponsor
- Centers for Medicare and Medicaid Services/ Coverage and Analysis Group · Federal
This trial is looking for Medicare patients diagnosed with mild Alzheimer's disease or mild cognitive impairment due to Alzheimer's disease. Participants will help collect data to support treatments for these conditions.
You may be able to join if
- I have been diagnosed with mild cognitive impairment due to Alzheimer's disease
- I have been diagnosed with mild Alzheimer's disease
- I have confirmed presence of amyloid beta pathology consistent with Alzheimer's disease
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThe Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).
Loading trial locations…